Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today

被引：2
|
作者：
Bloomgarden, Zachary T. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2019年 / 157卷
关键词：
DIPEPTIDYL-PEPTIDASE-IV; ALL-CAUSE MORTALITY; CARDIOVASCULAR EVENTS; METAANALYSIS; SITAGLIPTIN; RISK;
D O I：
10.1016/j.diabres.2019.107906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Computational Identification of Inhibitors Against DPP-IV for Checking Type-2 Diabetes (vol 14, pg 66, 2017)
    Gupta, Sarvesh Kumar
    Chaudhary, Kamal Kumar
    Raj, Utkarsh
    Mishra, Nidhi
    LETTERS IN DRUG DESIGN & DISCOVERY, 2020, 17 (02) : 226 - 226
  • [32] Investigation of medicinal plants from Madagascar against DPP-IV linked to type 2 diabetes
    Beidokhti, M. N.
    Lobbens, E. S.
    Rasoavaivo, P.
    Staerk, D.
    Jager, A. K.
    SOUTH AFRICAN JOURNAL OF BOTANY, 2018, 115 : 113 - 119
  • [33] DPP-IV resistant GLP4 analogues as potential type 2 diabetes therapies
    Kanda, F.
    Sharma, R. P.
    Hodgkinson, C. P.
    BIOPOLYMERS, 2007, 88 (04) : 578 - 578
  • [34] Topical administration of dipeptidyl peptidase IV (DPP-IV) inhibitors prevents retinal neurodegeneration in experimental diabetes
    Hernandez, Cristina
    Bogdanov, Patricia
    Sola-Adell, Cristina
    Sampedro, Joel
    Valeri, Marta
    Simo-Servat, Olga
    Herance, Raul
    Simo, Rafael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [35] DPP-IV Inhibitors from natural sources: An alternative approach for treatment and management of diabetes
    Sharma, Divya
    Kumar, Sandeep
    Kumar, Sunil
    Kumar, Dinesh
    INDIAN JOURNAL OF NATURAL PRODUCTS AND RESOURCES, 2019, 10 (04): : 227 - 237
  • [36] TOPICAL ADMINISTRATION OF DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS PREVENTS RETINAL NEURODEGENERATION IN EXPERIMENTAL DIABETES
    Hernandez, C.
    Bogdanov, P.
    Sola-Adell, C.
    Sampedro, J.
    Simo-Servat, O.
    Garcia-Ramirez, M.
    Simo, R.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2017, 27 (03) : E113 - E113
  • [37] Series: Implications of the recent CVOTs in type 2 diabetes Impact on guidelines: The endocrinologist point of view
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 159
  • [38] N-substitututed glycyl 2-cyanopyrrolidines as a new family of DPP-IV inhibitors and their potential use in type 2 diabetes.
    Villhauer, EB
    Anderson, RC
    Balkan, B
    Barilla, D
    Brinkman, JA
    Dunn, E
    Dunning, B
    Graham, ED
    Gu, HPH
    Gutierrez, CM
    Hamilton, BH
    Kwasnik, LA
    Li, X
    Mangold, BL
    Maniara, WM
    Miserendino-Molteni, R
    Mone, M
    Nader, GB
    Ramos, KL
    Russell, ME
    Rothenberg, PL
    Tullman, RH
    Valentin, M
    Walter, RE
    Weldon, SC
    Hughes, TE
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U60 - U60
  • [39] Design, synthesis and biological evaluation of novel pyrazolo-pyrimidinones as DPP-IV inhibitors in diabetes
    Sagar, Sneha R.
    Agarwal, Jessica K.
    Pandya, Dhaivat H.
    Dash, Ranjeet Prasad
    Nivsarkar, Manish
    Vasu, Kamala K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (20) : 4428 - 4433
  • [40] Indole Alkaloids as New Leads for the Design and Development of Novel DPP-IV Inhibitors for the Treatment of Diabetes
    Dhiraviam, Kannan Narayanan
    Balasubramanian, Suganthana
    Jayavel, Sridhar
    CURRENT BIOINFORMATICS, 2018, 13 (02) : 157 - 169
12345